Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Lysosomal membrane ascorbate-dependent ferrireductase CYB561A3 is a transmembrane enzyme of the cytochrome b561 family, encoded by the CYB561A3 gene. It mediates ascorbate-dependent electron transport across lysosomal and endosomal membranes, using ascorbic acid (vitamin C) as an electron donor to reduce ferric iron (Fe³⁺) to ferrous iron (Fe²⁺). This reduction is a key step enabling iron export from lysosomes and is essential for maintaining intracellular iron homeostasis. CYB561A3 is especially important in certain cell types, such as Burkitt lymphoma cells, in which its depletion causes iron starvation, lysosomal and mitochondrial dysfunction, and impaired proliferation—defects that can be rescued by ascorbate or direct iron supplementation. Its expression has been linked to immune defense mechanisms in macrophages as well as to dysregulated states in various diseases, highlighting CYB561A3 as both a potential therapeutic target and a biomarker for iron metabolism disorders
Drugs targeting CYB561A3 would be expected to modulate ferrireductase activity, affecting lysosomal iron reduction and cellular iron availability
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Lysosomal membrane ascorbate-dependent ferrireductase CYB561A3 (CYB561A3).